Detailed Information

Cited 16 time in webofscience Cited 13 time in scopus
Metadata Downloads

Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial

Authors
Yim, Hyung JoonSeo, Yeon SeokYoon, Eileen L.Kim, Chang WookLee, Chang DonPark, Sang HoonLee, Myung SeokPark, Choong KeeChae, Hee BokKim, Moon YoungBaik, Soon KooKim, Yun SooKim, Ju HyunIl Lee, JungLee, Jin WooHong, Sun PyoUm, Soon Ho
Issue Date
Feb-2013
Publisher
WILEY
Keywords
adefovir; chronic hepatitis B; entecavir; lamivudine; resistance
Citation
LIVER INTERNATIONAL, v.33, no.2, pp.244 - 254
Indexed
SCIE
SCOPUS
Journal Title
LIVER INTERNATIONAL
Volume
33
Number
2
Start Page
244
End Page
254
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/10998
DOI
10.1111/liv.12036
ISSN
1478-3223
Abstract
Background Management of lamivudine-resistant chronic hepatitis B (CHB) remains challenging, as inappropriate choice of treatment may cause multidrug resistance. Until now, randomized trials directly comparing adding adefovir and switching to entecavir monotherapy have not been reported. Aims This multicentre prospective randomized study was designed to compare the efficacy of these two strategies. Methods Two hundred and nineteen lamivudine-resistant CHB patients were randomized to either adefovirlamivudine combination group or entecavir monotherapy group (n = 110 vs. 109), and followed up for 24 months. Results One hundred and eighty patients completed this study. At month 24, virological response rate [hepatitis B virus (HBV) DNA <60 IU/ml] was higher in the adefovirlamivudine combination group compared with entecavir group (56.7% vs. 40%, P = 0.025), although biochemical and serological response rates were not significantly different. Genotypic resistance (9.2% vs. 24.6%, P = 0.005) and combined viral breakthrough (2.0% vs. 17.6%, P < 0.001) were more frequent in the entecavir group. However, by subgroup analysis, virological response rates were not significantly different between the two therapies in HBeAg-positive patients (44.9% vs. 35.7%, P = 0.268) or in patients with high baseline HBV DNA (=7 log IU/ml) (40.7% vs. 31.3%, P = 0.320) at month 24. Conclusion This study showed that adefovirlamivudine combination provides significantly higher antiviral efficacy and the lower resistance rate compared with the entecavir monotherapy in the management of lamivudine-resistant CHB. However, it had limited efficacy in HBeAg-positive patients or in patients with high baseline HBV DNA.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yim, Hyung Joon photo

Yim, Hyung Joon
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE